Press Centre
Press Releases
Total Voting Rights
30 June 2009
Phynova Group plc
("the Company")
Total Voting Rights
The Company announces that, pursuant to the requirements of the Disclosure and Transparency Rules, the total number of voting rights in respect of each class of share in issue and admitted to trading on AIM at the date of this announcement is as follows:
For further information, please contact:
Phynova Group PLC
Steve Harris (Non-Executive Chairman) +44 (0) 1993 880700
Tony Mills (CEO Phynova Limited)
Robert Miller (CEO Phynova China Limited)
Nominated Adviser and Broker:
John East & Partners Limited, a subsidiary of Merchant Securities PLC +44 (0) 20 7628 2200
John East/Simon Clements
Notes to Editors:
About Phynova
Phynova is a UK company developing new prescription pharmaceuticals derived from plants used in Chinese medicines. The Company is focused on viral and bacterial diseases, metabolic diseases and cancer. Phynova´s lead product for hepatitis C has now completed a Phase I/II trial in the US. One further product, for post-operative ileus, is targeted for entry to the clinic and there are a further four products in preclinical development.
For further information please visit www.phynova.com.
01/07/2009
<< Back | See all current Press releses